• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by National Vision Holdings Inc. (Amendment)

    2/13/24 5:09:41 PM ET
    $EYE
    Ophthalmic Goods
    Health Care
    Get the next $EYE alert in real time by email
    SC 13G/A 1 tv01517-nationalvisionholdin.htm SCHEDULE 13G/A nationalvisionholdingsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 6)*

    Name of issuer:  National Vision Holdings Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  63845R107

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  63845R107

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    57,172

    7.  SOLE DISPOSITIVE POWER

    8,741,417

    8.  SHARED DISPOSITIVE POWER

    141,112

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    8,882,529

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    11.35%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    National Vision Holdings Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    2435 Commerce Avenue, Building 2200
    Duluth, GA 30096-4980

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    63845R107

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $EYE alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $EYE

    DatePrice TargetRatingAnalyst
    7/8/2025$30.00Equal Weight → Overweight
    Barclays
    5/9/2025$21.00Neutral → Buy
    Citigroup
    5/7/2025Underperform → Buy
    BofA Securities
    10/17/2023$25.00 → $16.00Buy → Neutral
    Goldman
    7/27/2023$28.00 → $22.00Buy → Neutral
    Citigroup
    7/27/2023$30.00 → $21.00Overweight → Equal Weight
    Wells Fargo
    5/2/2023Overweight → Equal Weight
    Barclays
    3/31/2023$23.00Hold → Buy
    Loop Capital
    More analyst ratings

    $EYE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Peeler D Randolph bought $264,200 worth of shares (25,000 units at $10.57) (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      8/14/24 4:27:52 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Director Hepner Virginia A bought $10,365 worth of shares (1,000 units at $10.37), increasing direct ownership by 3% to 36,635 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      8/14/24 4:26:51 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Fahs L Reade bought $299,200 worth of shares (20,000 units at $14.96), increasing direct ownership by 3% to 633,097 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      5/14/24 8:01:46 AM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    SEC Filings

    See more
    • National Vision Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - National Vision Holdings, Inc. (0001710155) (Filer)

      6/23/25 5:04:58 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • SEC Form 10-Q filed by National Vision Holdings Inc.

      10-Q - National Vision Holdings, Inc. (0001710155) (Filer)

      5/8/25 8:36:28 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - National Vision Holdings, Inc. (0001710155) (Filer)

      5/7/25 6:05:18 AM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • National Vision upgraded by Barclays with a new price target

      Barclays upgraded National Vision from Equal Weight to Overweight and set a new price target of $30.00

      7/8/25 8:23:14 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision upgraded by Citigroup with a new price target

      Citigroup upgraded National Vision from Neutral to Buy and set a new price target of $21.00

      5/9/25 8:39:42 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision upgraded by BofA Securities

      BofA Securities upgraded National Vision from Underperform to Buy

      5/7/25 2:46:43 PM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • National Vision Announces Participation in William Blair Growth Stock Conference

      National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced that the Company is scheduled to present at the 45th annual William Blair Growth Stock Conference on Wednesday, June 4, 2025, at 9:20 a.m. Central Time. A live webcast of the presentation can be accessed in the "Investors" section of the Company's website at www.nationalvision.com/investors. The webcast will be archived and available on the website shortly after the event. About National Vision Holdings, Inc. National Vision Holdings, Inc. (NASDAQ:EYE) is one of the largest optical retail companies in the United States with over 1,200 stores in 38 states and Puerto Rico. With a mission of hel

      5/21/25 4:05:00 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Announces Settlement of 2025 Convertible Senior Notes

      National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced the settlement of the remaining $84.8 million aggregate principal amount of 2.5% unsecured convertible senior notes due May 15, 2025 (the "2025 Convertible Notes"). The settlement was made with $59.8 million from cash on hand and the remaining borrowed under the Company's revolving credit facility. Chris Laden, Chief Financial Officer of National Vision, said, "Our strong cash generation and solid balance sheet support our ongoing approach to a balanced capital allocation strategy, which has included the opportunistic repurchases and the final settlement of our convertible notes. As we look ahe

      5/15/25 4:05:00 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Holdings, Inc. Reports First Quarter 2025 Financial Results

      Successful Execution of New Transformation Initiatives and Cost Reduction Actions Delivered Strong First Quarter First quarter 2025 highlights compared to Q1 2024: Net revenue from continuing operations of $510.3 million, an increase of 5.7% Comparable store sales growth of 4.1% and Adjusted Comparable Store Sales Growth of 5.5% represented the 9th consecutive quarter of positive growth Income from continuing operations of $14.2 million, Diluted EPS from continuing operations of $0.18 Adjusted Operating Income from continuing operations of $41.3 million Adjusted Diluted EPS from continuing operations of $0.34 Raises fiscal 2025 outlook National Vision Holdings, Inc. (NASDAQ:E

      5/7/25 6:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President, America's Best Banner Mark converted options into 11,728 shares and covered exercise/tax liability with 3,462 shares (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      7/9/25 4:21:56 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Director Zulla Caitlin was granted 10,870 units of Restricted Stock Units, increasing direct ownership by 99% to 21,880 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      6/23/25 4:40:50 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Director Ofarrell Susan C was granted 9,674 shares, increasing direct ownership by 76% to 22,333 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      6/23/25 4:39:21 PM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Leadership Updates

    Live Leadership Updates

    See more
    • National Vision Appoints Alex Wilkes as CEO

      Reade Fahs to Assume Executive Chairman Position Transition Effective August 1, 2025 National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced that its Board of Directors has appointed Alex Wilkes as the Company's next Chief Executive Officer, effective August 1, 2025, and he will join the Company's Board at that time. Mr. Wilkes succeeds Reade Fahs who will assume the role of Executive Chairman of the Board. Mr. Fahs will continue to work closely with Mr. Wilkes, ensuring a smooth transition. "National Vision has been on a journey of significant transformation for the past few years, and today I am pleased to announce the next chapter in that tran

      4/29/25 6:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Appoints Jim McGrann and Michael Nicholson to Board of Directors

      Enters into Cooperation Agreement with Engine Capital National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced the appointment of two new independent directors, Jim McGrann and Michael Nicholson to its Board of Directors (the "Board"), effective March 17, 2025. Mr. McGrann will serve on the Board's Compensation Committee and Mr. Nicholson will serve on the Board's Audit Committee and Nominating and Corporate Governance Committee. With the addition of Messrs. McGrann and Nicholson, the Board will expand from 9 to 11 members. The Board has also formed an Advisory Committee that will help oversee National Vision's ongoing transformation initiatives with

      3/17/25 4:05:00 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Appoints Christopher Laden as Chief Financial Officer

      National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced the appointment of Christopher Laden as Chief Financial Officer, effective March 31, 2025. He will succeed Melissa Rasmussen who, as previously announced, will step down from the Company, effective March 3, 2025. "We are thrilled to welcome Chris to National Vision. He has a proven track record of successfully developing finance organizations into strong cross-functional business partners by focusing on accountability, employee development, and driving efficiencies through the use of digitization. His experience in both the service and optical industries will be instrumental as we move forward

      2/26/25 5:59:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Financials

    Live finance-specific insights

    See more
    • National Vision Holdings, Inc. Reports First Quarter 2025 Financial Results

      Successful Execution of New Transformation Initiatives and Cost Reduction Actions Delivered Strong First Quarter First quarter 2025 highlights compared to Q1 2024: Net revenue from continuing operations of $510.3 million, an increase of 5.7% Comparable store sales growth of 4.1% and Adjusted Comparable Store Sales Growth of 5.5% represented the 9th consecutive quarter of positive growth Income from continuing operations of $14.2 million, Diluted EPS from continuing operations of $0.18 Adjusted Operating Income from continuing operations of $41.3 million Adjusted Diluted EPS from continuing operations of $0.34 Raises fiscal 2025 outlook National Vision Holdings, Inc. (NASDAQ:E

      5/7/25 6:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Holdings, Inc. Announces First Quarter 2025 Earnings Release and Conference Call

      National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") will report its first quarter 2025 financial results before the market opens on Wednesday, May 7, 2025, and will host a conference call at 8:30 a.m. Eastern Time. To pre-register for the conference call and obtain a dial-in number and passcode, please refer to the "Investors" section of the Company's website at www.nationalvision.com/investors. A live audio webcast of the conference call, together with related materials, will be available online in the "Investors" section of the Company's website. A replay of the audio webcast will be available shortly after the broadcast. About National Vision Holdings, Inc.

      4/24/25 8:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Holdings, Inc. Reports Fourth Quarter and Fiscal 2024 Financial Results

      Strong Fourth Quarter Results Reflect Successful Execution on Store-Level Transformation Initiatives Introduced Targeted Initiatives to Broaden Appeal and Expand Customer Base Actions Taken to Reduce Costs and Strengthen Profitability Fourth quarter 2024 highlights: Net revenue from continuing operations of $437.3 million, an increase of 3.9% as compared to Q4 2023 Comparable store sales growth of 2.6% and Adjusted Comparable Store Sales Growth of 1.5% as compared to Q4 2023 Net loss from continuing operations of $(29.4) million, Diluted EPS from continuing operations of $(0.37) Adjusted Operating Income from continuing operations increased to $3.2 million from $(2.7) mill

      2/26/25 6:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

      SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

      11/14/24 12:33:08 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

      SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

      11/12/24 4:45:48 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

      SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

      11/4/24 1:18:26 PM ET
      $EYE
      Ophthalmic Goods
      Health Care